$99.97
Research Studies:
FREE Shipping on
orders over $200
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are intended solely for research and laboratory use. These products are not intended for human or animal consumption. They are not medicines or drugs and have not been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. Any form of bodily introduction is strictly prohibited by law.
GHK-Cu 100mg is a research-use-only laboratory material supplied for controlled research workflows, compound characterization, and analytical documentation review. It is manufactured under rigorous quality standards to support consistency, traceability, and batch-specific verification for qualified laboratory settings.
GHK-Cu 100mg is intended strictly for laboratory research use only. This product is not intended for human or animal consumption, therapeutic use, diagnostic use, clinical use, veterinary use, or as a food, drug, cosmetic, dietary supplement, or household product.
| CAS No. | 49557-75-7 |
|---|---|
| Purity | ≥99% |
| Sequence | Gly-His-Lys•2(Cu•2H2O) |
| Molecular Formula | C14H24N6O4 |
| Molecular Weight | 340.38 g/mol |
| Synthesis | Solid-phase synthesis |
| Format | Lyophilized powder |
| Solubility | Soluble in water or dilute acid |
| Stability & Storage | Stable for up to 24 months at -20°C. After reconstitution, may be stored at 4°C for up to 4 weeks or at -20°C for up to 6 months. |
| Applications | Tissue regeneration, wound healing, cosmetics, dermatology |
| Appearance | Blue to green powder |
| Shipping Conditions | Shipped at ambient temperature; once received, store at -20°C |
| Regulatory/Compliance | Manufactured in a facility that adheres to cGMP guidelines |
| Safety Information | Refer to provided MSDS |
Consider these supplementary peptides for a comprehensive research approach.
Researchers evaluating where to buy GHK-Cu for research should begin with compound identity, batch-specific documentation, and RUO labeling rather than consumer-facing claims. GHK-Cu is a copper peptide complex connected to glycyl-L-histidyl-L-lysine records and copper-component records in official chemical databases [1] [2] [3]. This Pure Lab Peptides guide frames GHK-Cu as a research-use-only laboratory material and separates published literature from product positioning.
To buy GHK-Cu for research in a documentation-led way, research teams should verify RUO labeling, the compound name, batch-specific COA, analytical method, purity record, identity record, lot number, and storage documentation before procurement. Products discussed in this article are intended for laboratory research use only and are not intended for human or animal consumption. Published GHK-Cu literature should be interpreted as model-specific context, not product positioning [6].
A commercial query becomes safer when it is framed around research procurement, not personal selection. For this page, the safe phrase is buy GHK-Cu for research, which directs attention toward laboratory documentation, not consumer outcomes.
That shift matters because product-page SEO can drift when broad peptide keywords are copied from search data without context. The safer approach is to answer the commercial question through RUO labeling, COA availability, analytical testing, and batch traceability.
The first review point is the match between the product listing, the label, and the batch-specific certificate of analysis. A useful COA should identify the compound, lot, testing method, testing date, purity result, and source of the analytical record.
Researchers should also check whether the documentation distinguishes peptide purity from peptide identity. HPLC can support purity review, while LC-MS or related mass-spectrometry methods can add identity evidence for synthetic peptide materials [14] [15].
RUO labeling sets the intended research context for the page and the material. FDA guidance for certain laboratory products shows how RUO labeling is used to separate research-phase materials from diagnostic representation, which is a useful compliance reference point even when the product category is not an IVD product [17].
For GHK-Cu, RUO language should keep the page focused on laboratory research, analytical review, and documentation. It should not imply personal selection, clinical positioning, or consumer-facing product performance.
GHK-Cu is commonly described as a copper peptide complex related to the tripeptide GHK. PubChem lists GHK-Cu as a copper-containing compound and identifies glycyl-L-histidyl-L-lysine as the parent compound in the record [1] [2].
Research literature often discusses GHK and GHK-Cu together because the peptide and copper-complex context are closely connected. That relationship is useful for compound identity review, but a product page should still specify the exact listing name and batch documentation.
GHK-Cu belongs in the copper peptide research lane. The copper component matters because copper coordination changes how the peptide complex is discussed in chemical and biological literature.
Classic coordination studies examined interaction between Cu(II) and glycyl-L-histidyl-L-lysine using methods such as potentiometric titration and visible-absorption spectrophotometry [4]. Later work compared copper complexes of GHK and synthetic analogues using multiple chemical-characterization methods [5].
Glycyl-L-histidyl-L-lysine copper fits as a copper-bound tripeptide research entity. The GHK record gives the peptide sequence context, while the copper record identifies the elemental component that appears in the complex [2] [3].
For product-page review, that means the listing should not rely only on a familiar abbreviation. It should provide enough peptide information for a lab team to connect the compound name, COA, and analytical data.
The amino acid sequence helps researchers confirm that the listed peptide corresponds to the expected GHK identity. PubChem records the GHK sequence as glycyl-histidyl-lysine, which gives a baseline for documentation comparison [2].
Sequence context is not the same as a full analytical confirmation. It is one piece of the documentation file that should be reviewed alongside mass data, chromatographic data, and lot-specific records.
Copper peptide research around GHK-Cu includes chemical coordination, fibroblast culture models, extracellular matrix literature, and gene-expression analysis. The research lane is best described as copper peptide and cellular pathway research, not consumer-facing positioning.
The key research boundary is simple: literature context can describe what academic models examine, while product copy should describe documentation and RUO scope.
Published reviews describe GHK as a naturally occurring tripeptide studied across multiple cellular pathway models [6]. Some literature examines gene-expression signatures, matrix-related pathways, and fibroblast model variables.
A product page should not turn those pathway discussions into promises. Instead, it should explain how pathway context helps researchers understand why a compound appears in the literature and why documentation should be reviewed carefully.
Extracellular matrix literature is relevant because several studies have used fibroblast or related cell models to examine matrix-associated variables. One study investigated sulfated glycosaminoglycan synthesis in relation to the GHK-Cu complex [7].
That type of literature belongs in an evidence summary, not a claim about a research material. RUO copy should describe the model, the measured variable, and the limitation.
Pathway relevance means a compound appears in research models connected to a pathway or biological process. It does not mean a supplier product has been evaluated for the same context.
This is especially important for GHK-Cu because many search terms around copper peptide products come from appearance-focused or wellness-oriented language. A research product page should keep the focus on analytical identity, COA review, and literature interpretation.
The product-page task is to serve research procurement intent without becoming a consumer buying guide. Pure Lab Peptides should present GHK-Cu as an RUO peptide material with documentation, not as a product tied to outcomes.
That structure still serves commercial research searchers. It gives qualified research buyers a practical path for evaluating identity, batch records, and supplier documentation.
The phrase buy GHK-Cu for research should lead to a documentation checklist. It should not lead to claims, personal guidance, or unsupported comparisons.
A documentation-led page answers the procurement question by showing what to verify: product name, COA, HPLC record, LC-MS record, lot traceability, supplier documentation, and storage notes.
A research material listing should clarify the target compound, research-use-only status, supplied form, and available documentation. If a peptide is supplied in lyophilized form, the listing should make that status clear without turning storage notes into practical personal guidance.
The listing should also avoid variant-specific SEO targeting. Catalog amounts, when present, should remain catalog specifications rather than separate search targets.
Related products should be grouped by research lane, not by consumer-facing goals. For GHK-Cu, the appropriate lane is copper peptide research and cellular pathway research.
This helps prevent random entity stacking. It also keeps internal navigation focused on research peptide documentation, COA review, and same-lane research materials.
Published literature frames GHK-Cu through compound identity, copper coordination, in vitro models, matrix-related research, and gene-expression analysis. It does not validate a supplier product unless that product’s specific batch has its own documentation.
That distinction is central to RUO product pages. Literature can help readers understand the compound’s research context, while COA and testing records help evaluate the listed material.
Preclinical and in vitro literature can show what researchers investigated under defined model conditions. For example, fibroblast culture studies have examined matrix metalloproteinase-2 expression and related matrix remodeling variables in the context of GHK-Cu [8].
Those findings remain model-specific. They should not be rewritten as product claims, consumer outcomes, or expected product performance.
Product copy should state what the literature category is: database record, chemical characterization, in vitro model, preclinical literature, review article, or analytical method source. This helps readers separate the strength of the source from the scope of the claim.
Some published literature outside the scope of RUO product use has examined this compound class in human study settings. That literature should not be interpreted as a use claim for research-use-only materials.
A supplier page should not imply that a research material has the same status as a compound studied in a paper. The batch-specific material needs its own COA and identity documentation.
The safer editorial rule is to summarize literature as literature. Then return to the product-page task: compound identity, analytical testing, lot traceability, and RUO positioning.
A strong evidence framework prevents overstatement. It asks what kind of source is being used, what model is involved, what was measured, and what the product page can safely say.
| Research Area | What Literature Examines | Evidence Type | RUO Interpretation |
|---|---|---|---|
| Compound identity | GHK-Cu, parent GHK, and copper-component database records [1] [2] [3] | Official database | Supports identity review, not product claims |
| Copper complex chemistry | Cu(II) interaction with glycyl-L-histidyl-L-lysine [4] [5] | Chemical characterization | Supports copper-complex context |
| Matrix-associated cell models | Sulfated glycosaminoglycan synthesis and fibroblast variables [7] [8] | In vitro literature | Model-specific context only |
| Gene-expression analysis | Connectivity Map methods and GHK-related signatures [9] [10] [11] | Bioinformatics and cell-model literature | Literature interpretation, not supplier claim |
| Analytical verification | LC-MS and LC-HRMS for peptide characterization [14] [15] | Analytical chemistry | Supports identity and impurity review |
A good source-quality filter ranks official database records, peer-reviewed studies, review articles, analytical chemistry papers, and official standards above marketing claims. It also asks whether the source describes GHK, GHK-Cu, a related copper complex, or a different peptide entity.
The Connectivity Map literature is useful for understanding gene-expression methods. Lamb and colleagues described the Connectivity Map as a way to connect small molecules, genes, and disease signatures through gene-expression profiles, and Broad’s CMap program describes large-scale perturbational expression profiling [9] [10].
Research findings should be summarized with neutral verbs: examined, evaluated, characterized, reported, compared, or observed. For GHK-Cu, that means writing about compound records, copper coordination, fibroblast models, matrix-associated variables, or gene-expression analysis.
This style keeps the article useful without turning academic findings into product claims.
Uncertainty signals include model type, limited scope, indirect evidence, source age, and whether the source is a review or original study. These signals help research buyers see the difference between a database fact, a chemical-characterization study, and a biological model.
For product pages, uncertainty is not a weakness. It is part of honest RUO communication.
Claim boundaries protect the research purpose of the page. They keep scientific literature separate from product positioning, especially when search terms contain consumer-facing or clinical-use language.
Phrases about product effects or product performance require careful framing because they can become product claims if separated from model-specific literature context. The page should always return to documentation: COA, testing method, identity, lot number, label, and RUO status.
Search intent can drift when a keyword implies a consumer goal rather than research procurement. That drift is common in peptide-related search data because many queries mix compound names with broad outcome language.
For GHK-Cu, the safer page architecture does not answer those consumer-style queries. It redirects the topic toward research literature, compound identity, and documentation review.
Commercial copy can still be accurate and useful without making claims. The page can explain what research buyers should verify and why each document matters.
This is where Pure Lab Peptides can provide practical value. The commercial answer is not “what the compound does”; it is “what documentation should be reviewed before procurement.”
Product-page language should avoid becoming therapeutic language, wellness language, appearance-focused language, or administration-focused language. It should also avoid turning literature findings into implied product claims.
A clean RUO page keeps the reader anchored in procurement documentation, not consumer interpretation.
COA documentation matters because it connects the product listing to a specific batch record. It helps researchers review whether the listed peptide material has analytical support.
Official analytical-method guidance emphasizes that validation characteristics are part of a general framework for analytical procedures, and FDA methods guidance discusses documentation that supports identity, quality, purity, and potency in regulated drug and biologic contexts [12] [13]. For RUO research materials, those sources provide useful analytical concepts without changing the product’s intended research status.
Certificates of analysis should identify the compound name, lot number, analytical method, testing date, and reported values. They should also make it possible to connect the COA back to the product label and listing.
If a COA does not match the product record, it should not be treated as strong documentation for that material. Batch matching is the core requirement.
Researchers review COA consistency by comparing the product name, lot number, method, date, and analytical result across the label, listing, and COA. If third-party testing is listed, the laboratory identity and report scope should be clear.
ISO/IEC 17025 is a widely used standard for testing and calibration laboratories, and ISO describes it as a way for laboratories to demonstrate competent operation and valid results [16]. Accreditation language should still be checked against the actual test report, not assumed from a supplier statement.
Analytical testing review should combine purity screening with identity support. HPLC, LC-MS, and high-resolution mass spectrometry can each contribute different information when used in a suitable analytical workflow.
The USP notes that peptide standards and analytical reference materials can support method development, method validation, equipment qualification, and quality control for peptide drug substance and product batches [19]. For RUO product pages, the relevant lesson is documentation clarity, not regulated-product equivalence.
HPLC can support peptide purity review by separating components and generating chromatographic records. A purity percentage should be interpreted with the method, chromatogram, and batch context.
A purity number alone does not establish complete identity. FDA-linked peptide quality research has noted that HPLC-UV methods can be insufficient for distinguishing some peptide impurities or changed peptide sequences [15].
LC-MS supports identity review by pairing chromatography with mass-spectrometry information. Reviews of peptide LC-MS methods describe the value of mass-spectrometric detection for peptide analysis and quantification [20].
Numbered lab-test verification workflow for documentation review:
Lot traceability links the product label, COA, testing record, storage note, and procurement record. It helps a lab team determine whether the documents all refer to the same material.
Without lot-level matching, even a well-written COA has limited value. The document must map to the batch being evaluated.
Lot numbers connect the material to the batch-specific documentation file. They should appear consistently on the label, COA, supplier documentation, and internal procurement record.
This connection is especially important for peptide products because synthetic peptides can have batch-specific impurity profiles and stability considerations [14] [15].
COA dates and labels should align because timing and traceability affect document interpretation. A COA created for a different batch, date range, or listing does not provide the same confidence.
Researchers should treat every batch as its own documentation unit. A general claim is not a substitute for a batch-specific file.
Storage and handling documentation should describe the supplied form and the conditions expected for laboratory records. Many peptide materials are supplied in lyophilized form, and solid-state peptide literature notes that proteins and peptides are often formulated in solid state for stabilization during storage, while degradation can still occur in solid-state materials [18].
For a product-page article, the safe focus is documentation. The page should identify where storage information appears and how lab teams should record it.
Storage notes should clarify supplied form, labeled storage conditions, shipment notes, and any document source for handling requirements. They should not become personal guidance.
A research team’s internal record should preserve the supplier’s storage statement, the lot number, the COA, and the date the material entered the lab inventory.
Handling records support continuity by making it easier to reconstruct the chain of documentation. This matters when more than one lab member reviews the same peptide material.
A consistent record can include the product listing, COA, label image, lot number, receipt date, storage notation, and analytical files. That record supports research continuity without implying any non-research purpose.
Supplier documentation review is the practical core of the product page. Research buyers should compare what the supplier says with what the supplier documents.
The strongest pages do not rely on broad quality language alone. They show how the listing, COA, label, and analytical files connect.
Research buyers should compare RUO labeling, COA availability, batch specificity, analytical methods, lot traceability, and storage documentation. They should also compare how clearly each supplier separates published literature from product claims.
Useful supplier documentation includes:
Third-party testing can support documentation confidence when the report is batch-specific and method-specific. It should show what was tested, what method was used, when testing occurred, and how the result connects to the product lot.
Third-party tested language should not stand alone. It is strongest when paired with a report that can be reviewed.
Related products should support research navigation, not consumer comparison. For a GHK-Cu page, related products are best framed as same-lane research materials, peptide documentation resources, or analytical testing guides.
This approach keeps internal links and product modules aligned with RUO intent. It also prevents the page from drifting into wellness or appearance categories.
Related products should be categorized by research lane, compound class, or documentation topic. For GHK-Cu, the safest category is Copper Peptide Research.
A same-lane category can include research peptide documentation, COA review, analytical testing, and supplier evaluation pages. It should not group products by consumer outcomes.
Peptide products need separate documentation because each compound and batch can have different identity, purity, and analytical records. The fact that two products are both peptides does not mean their documentation can be shared.
This is why lot traceability and batch-specific COAs matter. They keep procurement review tied to the exact research material.
A final documentation review should answer one question: does the page give research buyers enough information to evaluate the material within RUO boundaries? If the answer depends on claims rather than documents, the page needs revision.
For GHK-Cu, the strongest final review covers identity, literature context, COA, analytical testing, lot traceability, storage documentation, supplier transparency, and claim boundaries.
Common misunderstandings to avoid:
Pure Lab Peptides supplies compounds for laboratory research use only. Products are not intended for human or animal consumption, diagnostic use, therapeutic use, clinical use, veterinary use, or as food, drugs, cosmetics, dietary supplements, or household products. Researchers are responsible for ensuring lawful, appropriate handling and use in accordance with applicable regulations and institutional guidelines.
Product documentation supports next-step review by giving research teams a clear file to examine before selection. The file should include the listing, label, COA, method notes, lot number, storage statement, and any available analytical data.
Review the product-page documentation, COA details, and RUO labeling before evaluating GHK-Cu for laboratory research.
Researchers should consider whether the GHK-Cu product page provides clear RUO labeling, batch-specific documentation, COA details, analytical testing information, and lot traceability. A documentation-first review helps keep buy GHK-Cu peptides intent focused on laboratory procurement rather than unsupported product claims. Supplier documentation should also clarify compound identity and research material records.
GHK-Cu is documented as a copper peptide research material tied to compound identity, peptide classification, and batch-level analytical records. In product-page review, the key question is whether the listed GHK-Cu copper peptide matches the COA, label, lot number, and identity documentation. Research documentation should remain separate from consumer-facing interpretation.
Researchers should evaluate GHK copper peptide listings by comparing the compound name, COA, lot number, testing method, and supplier documentation. Peptides online should be reviewed through documentation quality, not marketing language. Strong listings keep research-use-only status visible and provide enough information for technical procurement review.
Molecular weight matters for GHK-Cu documentation because it can help research teams compare compound identity details across product records, COA files, and analytical testing notes. It should not be treated as a standalone proof of identity. A stronger review pairs molecular weight context with HPLC, LC-MS, lot traceability, and batch-specific records.
Formulation language should be handled carefully on an RUO product page because it can shift attention away from documentation if framed too broadly. For GHK-Cu, formulation references should stay limited to research material description, supplied form, storage documentation, and lab record clarity. They should not imply non-research positioning.
Researchers should interpret in vitro research for GHK-Cu as model-specific literature context, not product-page proof. In vitro research can help explain why a compound appears in academic discussion, but it does not replace batch-specific COA review, peptide identity testing, or supplier documentation. RUO product pages should keep literature context separate from product claims.
The following authors are recognized for published research that helped shape the scientific context discussed in this article.
Author profile: PubMed Author Search
Loren Pickart authored and co-authored multiple publications connected to GHK, GHK-Cu, copper peptide research, and cellular pathway literature. His work is relevant to this article’s discussion of GHK-Cu as a research peptide because it provides background on compound identity, copper-complex context, and model-specific literature interpretation. The selected publications below are useful for understanding how GHK-Cu appears in the scientific record while keeping product-page discussion focused on RUO documentation, analytical review, and published literature boundaries.
Selected publications:
Author profile: SickKids Profile
Bibudhendra Sarkar’s published work is relevant to the copper coordination and peptide-complex background discussed in this GHK-Cu research page. His publications include studies examining copper(II) interaction with glycyl-L-histidyl-L-lysine using analytical and spectroscopic methods. That research context supports the article’s focus on copper peptide characterization, compound identity review, and careful interpretation of literature without converting model-specific findings into product claims.
Selected publications:
This research disclaimer clarifies how this page handles published literature and search language around GHK-Cu. In Copper Peptide Research content, terms such as skincare, GHK-Cu topical, hyaluronic acid, sensitive skin, fine lines, wrinkle, collagen production, and hair growth can drift into consumer-facing, wellness, clinical-use, or product-claim language when framed incorrectly. Related phrases such as injectable, clinical outcomes, absorption, bioavailability, efficacy, and effects also require careful separation from product positioning when they appear in broader literature or search contexts.
Here, those phrases are handled only as research-language examples, not product uses, outcomes, instructions, or recommendations. The focus remains on GHK-Cu identity, COA review, analytical testing, peptide purity, lot traceability, RUO labeling, product documentation, and published literature boundaries. Model-specific research context should remain separate from claims about any research-use-only material, and product-page language should stay centered on documentation review rather than consumer interpretation.
Our team is ready to assist you with any inquiries regarding our catalogue of peptides and their applications.
Discount Applied Successfully!
Your savings have been added to the cart.
There are no reviews yet.